Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
LB-P8 aims to modulate bile acids and reduce inflammation and fibrosis associated with Primary Sclerosing Cholangitis
LB-P8 has received both Orphan Drug Designation in 2022 and Fast Track Designation from the FDA in 2024. These designations are intended to expedite the development and review process for drugs addressing serious conditions with unmet medical needs
Company information 2025-03-21
…